Veltri Keith T
From the Department of Pharmacy Practice, Touro College of Pharmacy, New York, NY; and Department of Pharmacy, Montefiore Medical Center, Bronx, NY.
Cardiol Rev. 2018 Jan/Feb;26(1):50-53. doi: 10.1097/CRD.0000000000000174.
Cardiovascular disease is the leading cause of morbidity and mortality in the United States. Patients who survive a primary cerebrovascular or cardiovascular event are at increased risk of a subsequent occurrence. Antiplatelet therapy plays an essential role for secondary prevention in individuals with stroke, transient ischemic attack, acute or chronic artery disease, or peripheral arterial disease. Maintaining high-risk patients on low-dose aspirin therapy is a fundamental component of management. However, poor adherence, secondary to the drug's gastrointestinal side effects, has been associated with negative cardiovascular outcomes. Numerous studies have indicated that proton-pump inhibitors significantly reduce the risk of upper gastrointestinal adverse events in aspirin-treated patients. The US Food and Drug Administration approved Yosprala (Aralez Pharmaceuticals), a fixed-dose combination of delayed-release aspirin and immediate-release omeprazole, on September 15, 2016. It is the first product to become available in the United States that combines these 2 pharmacologic drug classes, and represents a new therapeutic option for patients and healthcare providers who strive to improve adherence to daily aspirin therapy.
心血管疾病是美国发病和死亡的主要原因。在原发性脑血管或心血管事件中幸存的患者再次发病的风险会增加。抗血小板治疗在中风、短暂性脑缺血发作、急性或慢性动脉疾病或外周动脉疾病患者的二级预防中起着至关重要的作用。让高危患者维持低剂量阿司匹林治疗是治疗的基本组成部分。然而，由于药物的胃肠道副作用导致的依从性差与不良心血管结局相关。大量研究表明，质子泵抑制剂可显著降低阿司匹林治疗患者发生上消化道不良事件的风险。2016年9月15日，美国食品药品监督管理局批准了Yosprala（Aralez制药公司），这是一种缓释阿司匹林和速释奥美拉唑的固定剂量组合。它是美国首个上市的将这两类药物联合使用的产品，为努力提高每日阿司匹林治疗依从性的患者和医疗服务提供者提供了一种新的治疗选择。
